Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival Results From the Valsartan Heart Failure Trial

• Published in: Circulation. Heart failure Vol. 9; no. 7
• Main Authors: Florea, Viorel G., Rector, Thomas S., Anand, Inder S., Cohn, Jay N.
• Format: Journal Article
• Language: English
• Published: United States 01.07.2016
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Aged; Angiotensin II Type 1 Receptor Blockers - adverse effects; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Biomarkers - blood; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Female; Heart Failure - diagnostic imaging; Heart Failure - drug therapy; Heart Failure - mortality; Heart Failure - physiopathology; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - therapeutic use; Recovery of Function; Stroke Volume - drug effects; Time Factors; Treatment Outcome; Valsartan - adverse effects; Valsartan - therapeutic use; Ventricular Function, Left - drug effects; blood pressure; heart failure; valsartan; biomarker; prognosis

Heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Whether HFiEF is clinically distinct from HF with persistently reduced ejection fraction remains to be validated. Of the 5010 subjects enrolled in the Valsartan Heart Failure Trial (Val-HeFT...